A FULLY INTEGRATED BIOPHARMACEUTICAL COMPANY WITH A ROBUST PIPELINE ACROSS MULTIPLE THERAPEUTIC AREAS INCLUDING ONCOLOGY, OPHTHALMOLOGY, AND IMMUNOLOGY.
Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics. Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated through net sales of its diversified portfolio of FDA-approved therapeutics.
The foundational therapy in our immuno-oncology pipeline is LOQTORZI, a next-generation PD-1 inhibitor. Through our acquisition of Surface Oncology, Coherus’ immuno-oncology pipeline includes casdozokitug, a novel first-in-class anti-IL-27 antibody currently being evaluated in Phase 1/2 clinical trials in lung and liver cancer. CHS-114 is a highly selective, competitively positioned anti-CCR8 antibody currently in a Phase 1/2 study as a monotherapy in patients with advanced solid tumors.
Coherus’ earlier-stage immuno-oncology pipeline includes CHS-006, a TIGIT-targeted antibody, being evaluated in combination with toripalimab, CHS-1000, a proprietary ILT4 antibody, and other immuno-therapies targeting novel pathways.
Coherus markets UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta®, CIMERLI® (ranibizumab-eqrn), a biosimilar of Lucentis®, YUSIMRY™ (adalimumab-aqvh) a biosimilar of Humira® and plans to launch LOQTORZI™ (toripalimab-tpzi), next-generation PD-1 inhibitor, in Q1 2024.
Coherus is headquartered in the heart of California’s Silicon Valley and composed of a team of industry veterans with decades of experience pioneering biologics companies.